Mediation of β-Endorphin by Ginsenoside Rh2 to Lower Plasma Glucose in Streptozotocin-Induced Diabetic Rats

Abstract

We investigated the plasma glucose-lowering mechanism(s) of Rh2, a ginsenoside derived from Panax ginseng, in rats with streptozotocin-induced diabetes (STZ-diabetic rats). After intravenous injection over 120 min into fasting STZ-diabetic rats, Rh2 decreased plasma glucose in a dose-dependent manner. In parallel to the lowering of plasma glucose, an increase of plasma β-endorphin-like immunoreactivity was observed. In addition, naloxone and naloxonazine at doses sufficient to block opioid μ-receptors inhibited the plasma glucose-lowering action of Rh2 in genetically wild-type, diabetic mice. In contrast, Rh2 failed to lower plasma glucose in opioid μ-receptor knockout diabetic mice. An increase in gene expression at both the mRNA and protein levels of glucose transporter subtype 4 (GLUT 4) was observed in soleus muscle obtained from STZ-diabetic rats treated with Rh2 three times daily for one day; this increase in expression was absent when opioid μ-receptors were blocked. In conclusion, our results suggest that ginsenoside Rh2 may lower plasma glucose in STZ-diabetic rats based on an increase in β-endorphin secretion that activates opioid μ-receptors thereby resulting in an increased expression of GLUT 4.

Ginsenoside Rh2 - streptozotocin-induced diabetic rats - β-endorphin - opioid μ-receptor

References

• 1 Lopez-Candales A. Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy.  J Med. 2001;  32 283-300
• 2 Lee F C. Facts about ginseng, the elixir of life. Elizabeth, NJ Hollyn International Corp 1992
• 3  V an Kampen J,  R obertson H,  H agg T,  D robitch R. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson’s disease.  Exp Neurol. 2003;  184 521-9
• 4 Kimura M, Waki I, Tanaka O, Nagai Y, Shibata S. Pharmacological sequential trials for the fractionation of components with hypoglycemic activity in alloxan diabetic mice from ginseng radix.  J Pharmacobiodyn. 1981;  4 402-9
• 5 Yokozawa T, Kobayashi T, Oura H, Kawashima Y. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb₂ in streptozotocin-diabetic rats.  Chem Pharm Bull. 1985;  33 869-72
• 6 Liu T P, Liu I M, Cheng J T. Improvement of insulin resistance by Panax ginseng in fructose-rich chow-fed rats.  Horm Metab Res. 2005;  37 146-51
• 7  D G, Kitts D D. Ginsenosides can inhibit proliferation and induce apoptosis in cultured leukemia and intestinal cells but effects vary according to the structure of the compounds.  Faseb J. 2003;  17 A762
• 8 Curry D L, Li C H. Stimulation of insulin secretion by beta-endorphin (1 - 27 and 1 - 31).  Life Sci. 1987;  40 2053-8
• 9 Cheng J T, Liu I M, Tzeng T F, Tsai C C, Lai T Y. Plasma glucose-lowering effect of beta-endorphin in streptozotocin-induced diabetic rats.  Horm Metab Res. 2002;  34 570-6
• 10 Cheng J T, Liu I M, Chi T C, Tzeng T F, Lu F H, Chang C J. Plasma glucose lowering effect of tramadol in streptozotocin-induced diabetic rats.  Diabetes. 2001;  50 2815-21
• 11 Liu I M, Chi T C, Shiao G C, Lin M T, Cheng J T. Loss of plasma glucose lowering response to cold stress in opioid mu-receptor knock-out diabetic mice.  Neurosci Lett. 2001;  307 81-4
• 12 Cefalu W T. Evolving strategies for insulin delivery and therapy.  Drugs. 2004;  64 1149-61
• 13 Pasternak G W. Pharmacological mechanisms of opioid analgesics.  Clin Neuropharmacol. 1993;  16 1-18
• 14 Berger J, Biswas C, Vicario P P, Strout H V, Saperstein R, Pilch P F. Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting.  Nature. 1989;  340 70-2